Wan Zhaojun, Wang Kai, Yin Xiangfu, Guo Xiangting, Cheng Guoli, Pan Jihong
Department of Oncology, Rizhao Hospital of Traditional Chinese Medicine, Rizhao, China.
Department of Oncology, The People's Hospital of Rizhao City, Rizhao, China.
Front Oncol. 2022 Jul 7;12:920990. doi: 10.3389/fonc.2022.920990. eCollection 2022.
Crizotinib is a tyrosine kinase inhibitor that has been found to be effective in the treatment of c-ros oncogene 1-positive non-small cell lung cancer. Although this targeted agent for treating cancer has shown superiority to standard chemotherapy in some ways, this drug has adverse effects, such as the development of renal abscesses. Some associated renal damage may disappear with crizotinib withdrawal. Hence, we present the case of a 58-year-old man with non-small cell lung cancer on crizotinib therapy who developed bilateral renal abnormal space-occupying lesions, successively which were difficult to identify using various imaging methods; even PET-CT highly suspected the right renal masses as malignant. Finally, the right renal lesions were confirmed as renal abscesses by postoperative pathology. The left renal lesion was considered as renal cysts through the lesion disappearing after crizotinib withdrawal. There have been very few reports in this respect, especially proved by various methods and confirmed by postoperative pathology. It is important to recognize this drug-related complication in order to avoid incorrect diagnosis and inadequate therapy. It is necessary to monitor renal changes after taking crizotinib.
克唑替尼是一种酪氨酸激酶抑制剂，已被发现对治疗c-ros癌基因1阳性非小细胞肺癌有效。尽管这种治疗癌症的靶向药物在某些方面已显示出优于标准化疗，但该药物有不良反应，如肾脓肿的发生。一些相关的肾损害可能在停用克唑替尼后消失。因此，我们报告一例58岁接受克唑替尼治疗的非小细胞肺癌男性患者，其双侧肾脏出现异常占位性病变，先后采用各种影像学方法均难以明确；即使PET-CT高度怀疑右肾肿块为恶性。最终，右肾病变经术后病理证实为肾脓肿。左肾病变在停用克唑替尼后病变消失，考虑为肾囊肿。这方面的报道非常少，尤其是通过各种方法证实并经术后病理确诊的。认识到这种与药物相关的并发症很重要，以避免误诊和治疗不足。服用克唑替尼后监测肾脏变化很有必要。
